BRPI0515562A - métodos e composições para avaliação do prognóstico do cáncer de mama - Google Patents

métodos e composições para avaliação do prognóstico do cáncer de mama

Info

Publication number
BRPI0515562A
BRPI0515562A BRPI0515562-2A BRPI0515562A BRPI0515562A BR PI0515562 A BRPI0515562 A BR PI0515562A BR PI0515562 A BRPI0515562 A BR PI0515562A BR PI0515562 A BRPI0515562 A BR PI0515562A
Authority
BR
Brazil
Prior art keywords
methods
prognosis
compositions
breast cancer
computer program
Prior art date
Application number
BRPI0515562-2A
Other languages
English (en)
Inventor
Timothy J Fischer
Clark M Whitehead
Douglas P Malinowski
Raphael Marcelpoil
Didier Morel
Original Assignee
Tripath Imaging Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tripath Imaging Inc filed Critical Tripath Imaging Inc
Publication of BRPI0515562A publication Critical patent/BRPI0515562A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus For Radiation Diagnosis (AREA)

Abstract

"MéTODOS E COMPOSIçõES PARA AVALIAçãO DO DIAGNóSTICO DO CáNCER DE MAMA". São fornecidos métodos e composições para avaliação do prognóstico de um paciente com câncer de mama, particularmente um paciente com câncer de mama em estágio inicial. Os métodos da invenção compreendem a detecção da expressão de pelo menos um, mais particularmente pelo menos dois biomarcadores em uma amostra corporal, em que a superexpressão do biomarcador ou uma combinação de bimarcadores é indicativa do prognóstico do câncer de mama. Em algumas modalidades, a amostra corporal é uma amostra de tecido mamário, particularmente uma amostra de tumor primário da mama. Os biomarcadores da invenção são proteínas e/ou genes cuja superexpressão é indicativa de um prognóstico bom ou ruim do câncer. Biomarcadores de interesse incluem proteínas e genes envolvidos na regulação do ciclo celular, replicação de DNA, transcrição, transdução de sinal, proliferação celular, invasão, proteólise ou metástase. Em alguns aspectos da invenção, a superexpressão de um biomarcador de interesse é detectada no nível protéico usando anticorpos específicos para o biomarcador ou no nível de ácido nucléico usando técnicas de hibridização de ácido nucléico.
BRPI0515562-2A 2004-09-22 2005-09-22 métodos e composições para avaliação do prognóstico do cáncer de mama BRPI0515562A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61196504P 2004-09-22 2004-09-22
US61207304P 2004-09-22 2004-09-22
PCT/US2005/034152 WO2006036788A2 (en) 2004-09-22 2005-09-22 Methods and compositions for evaluating breast cancer prognosis

Publications (1)

Publication Number Publication Date
BRPI0515562A true BRPI0515562A (pt) 2008-07-29

Family

ID=35695736

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0515581-9A BRPI0515581A (pt) 2004-09-22 2005-09-22 métodos e produtos de programa de computador para análise e otimização de candidatos marcadores para prognóstico de cáncer
BRPI0515562-2A BRPI0515562A (pt) 2004-09-22 2005-09-22 métodos e composições para avaliação do prognóstico do cáncer de mama

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0515581-9A BRPI0515581A (pt) 2004-09-22 2005-09-22 métodos e produtos de programa de computador para análise e otimização de candidatos marcadores para prognóstico de cáncer

Country Status (11)

Country Link
US (3) US20060063190A1 (pt)
EP (2) EP1800130B1 (pt)
JP (2) JP2008513032A (pt)
KR (2) KR20070061893A (pt)
AT (1) ATE520988T1 (pt)
AU (2) AU2005289728B2 (pt)
BR (2) BRPI0515581A (pt)
CA (2) CA2580937C (pt)
IL (2) IL182062A0 (pt)
MX (1) MX2007003502A (pt)
WO (2) WO2006036726A1 (pt)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8594410B2 (en) * 2006-08-28 2013-11-26 Definiens Ag Context driven image mining to generate image-based biomarkers
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20080131916A1 (en) * 2004-08-10 2008-06-05 Ring Brian Z Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy
EP2027465A2 (en) 2006-05-17 2009-02-25 Cellumen, Inc. Method for automated tissue analysis
KR100786759B1 (ko) * 2006-07-07 2007-12-18 김현기 Ｈｃｃｒ-1을 포함하는 유방암 예후 마커 및 비만 유도조성물
US20080108091A1 (en) * 2006-08-07 2008-05-08 Hennessy Bryan T Proteomic Patterns of Cancer Prognostic and Predictive Signatures
US8697373B2 (en) 2006-10-06 2014-04-15 Clarient Diagnostic Services, Inc. Reagents and methods for use in cancer diagnosis, classification and therapy
US8335360B2 (en) * 2007-05-14 2012-12-18 Historx, Inc. Compartment segregation by pixel characterization using image data clustering
WO2008156669A1 (en) 2007-06-15 2008-12-24 Historx, Inc. Method and system for standardizing microscope instruments
US20100221722A1 (en) * 2007-06-15 2010-09-02 University Of North Carolina At Chapel Hill Methods for evaluating breast cancer prognosis
CA2604317C (en) 2007-08-06 2017-02-28 Historx, Inc. Methods and system for validating sample images for quantitative immunoassays
CA2596204C (en) * 2007-08-07 2019-02-26 Historx, Inc. Method and system for determining an optimal dilution of a reagent
WO2009029810A1 (en) * 2007-08-31 2009-03-05 Historx, Inc. Automatic exposure time selection for imaging tissue
EP2034027A1 (en) * 2007-09-04 2009-03-11 Siemens Healthcare Diagnostics GmbH Molecular markers to predict response to chemotherapy and EGFR family inhibiton by targeted strategies
JP2010537659A (ja) * 2007-09-07 2010-12-09 ユニヴェルシテ リブル ドゥ ブリュッセル Ｅｒ−患者におけるガンの予後判定のための方法およびツール
GB0720113D0 (en) * 2007-10-15 2007-11-28 Cambridge Cancer Diagnostics L Diagnostic, prognostic and predictive testing for cancer
WO2009055480A2 (en) * 2007-10-22 2009-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tgf-beta gene expression signature in cancer prognosis
WO2009089521A2 (en) * 2008-01-10 2009-07-16 Nuvera Biosciences, Inc. Predictors for evaluating response to cancer therapy
WO2009158620A2 (en) * 2008-06-26 2009-12-30 Dana-Farber Cancer Institute, Inc. Signatures and determinants associated with metastasis methods of use thereof
ES2338843B1 (es) * 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
CN102159214A (zh) 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
ES2573945T3 (es) * 2008-09-16 2016-06-13 Novartis Ag Cuantificación reproducible de expresión de biomarcadores
US20100124747A1 (en) * 2008-11-03 2010-05-20 University Of Southern California Compositions and methods for diagnosis or prognosis of testicular cancer
WO2010062705A1 (en) * 2008-11-03 2010-06-03 Quest Diagnostics Investments Incorporated Cancer diagnosis using ki-67
KR101141103B1 (ko) * 2009-12-15 2012-05-02 계명대학교 산학협력단 임상진단 결정 규칙 생성 방법
BR112012024718A2 (pt) * 2010-03-31 2017-01-10 Sividon Diagnostics Gmbh método para a predição da recorrência de câncer da mama sob tratamento endócrino
EP2564200B8 (en) * 2010-04-27 2019-10-02 The Regents of The University of California Cancer biomarkers and methods of use thereof
MY191929A (en) 2010-06-03 2022-07-18 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
US9129426B2 (en) * 2010-08-31 2015-09-08 General Electric Company Motion compensation in image processing
FR2964744B1 (fr) * 2010-09-10 2015-04-03 Univ Versailles St Quentin En Yvelines Test pronostic de l'evolution d'une tumeur solide par analyse d'images
US10018631B2 (en) 2011-03-17 2018-07-10 Cernostics, Inc. Systems and compositions for diagnosing Barrett's esophagus and methods of using the same
WO2013010136A2 (en) 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20130096021A1 (en) * 2011-09-27 2013-04-18 Arul M. Chinnaiyan Recurrent gene fusions in breast cancer
US9115388B2 (en) 2011-11-01 2015-08-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gene signature for the prediction of NF-kappaB activity
EP2773390B1 (en) * 2011-11-03 2020-12-30 Tripath Imaging, Inc. Methods and compositions for preparing samples for immunostaining
US8885912B2 (en) * 2011-11-03 2014-11-11 General Electric Company Generate percentage of positive cells for biomarkers by normalizing and autothresholding the image intensity produced by immunohistochemistry technique
WO2013159099A2 (en) * 2012-04-20 2013-10-24 Memorial Sloan-Kettering Cancer Center Gene expression profiles associated with metastatic breast cancer
US8737709B2 (en) * 2012-04-30 2014-05-27 General Electric Company Systems and methods for performing correlation analysis on clinical outcome and characteristics of biological tissue
WO2013164280A1 (en) * 2012-04-30 2013-11-07 General Electric Company Systems and methods for analyzing biomarker co-localization in a biological tissue
EP2877598A1 (en) 2012-07-24 2015-06-03 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
US20150212087A1 (en) * 2012-07-27 2015-07-30 Centre Leon Berard Detection of the ERalpha/Src/PI3K Complex as Predictive Marker in Breast Cancer
JP2014123230A (ja) * 2012-12-20 2014-07-03 Sony Corp 画像処理装置、画像処理方法、及び、プログラム
CN103136333B (zh) * 2013-01-29 2016-08-10 冯力新 一种抽象属性的量化评价分析方法
CN103293321B (zh) * 2013-05-27 2015-05-13 北京大学 一种检测dna损伤诱导的早期核仁应激的试剂盒及其应用
ES2709509T3 (es) 2013-08-12 2019-04-16 Pharmacyclics Llc Procedimientos para el tratamiento de cáncer amplificado por HER2
US9519823B2 (en) * 2013-10-04 2016-12-13 The University Of Manchester Biomarker method
US9953417B2 (en) 2013-10-04 2018-04-24 The University Of Manchester Biomarker method
US9785752B1 (en) * 2014-02-25 2017-10-10 Flagship Biosciences, Inc. Method for stratifying and selecting candidates for receiving a specific therapeutic approach
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
WO2015148825A2 (en) * 2014-03-27 2015-10-01 Rong Li Methods and compositions for evaluating breast cancer patients
WO2015189264A1 (en) 2014-06-10 2015-12-17 Ventana Medical Systems, Inc. Predicting breast cancer recurrence directly from image features computed from digitized immunohistopathology tissue slides
KR20170084086A (ko) 2014-11-17 2017-07-19 아르노 테라퓨틱스 인코포레이티드 오나프리스톤 연장-방출 조성물 및 방법
WO2016090323A1 (en) 2014-12-05 2016-06-09 Prelude, Inc. Dcis recurrence and invasive breast cancer
US20180040120A1 (en) * 2014-12-29 2018-02-08 Flagship Biosciences, Inc. Methods for quantitative assessment of mononuclear cells in muscle tissue sections
KR101765999B1 (ko) 2015-01-21 2017-08-08 서울대학교산학협력단 암 바이오마커의 성능 평가 장치 및 방법
US10115187B2 (en) * 2015-01-30 2018-10-30 Raytheon Company Apparatus and processes for classifying and counting corn kernels
CA2998924A1 (en) 2015-09-25 2017-03-30 Context Biopharma Inc. Methods of making onapristone intermediates
US10962544B2 (en) 2015-11-25 2021-03-30 Cernostics, Inc. Methods of predicting progression of Barrett's esophagus
US20190113423A1 (en) * 2015-12-02 2019-04-18 Clearlight Diagnostics, LLC Methods for preparing and analyzing tumor tissue samples for detection and monitoring of cancers
US10548905B2 (en) 2015-12-15 2020-02-04 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
CN108882902B (zh) 2016-02-08 2022-08-30 医默观***公司 用于图像中对象的可视化和表征的***和方法
EP3430384A4 (en) * 2016-03-14 2019-07-31 Proteocyte Diagnostics Inc. AUTOMATED METHOD FOR THE ASSESSMENT OF CANCER RISK BY TISSUE SAMPLES AND SYSTEM THEREFOR
CA3017853A1 (en) 2016-03-14 2017-09-21 Somalogic, Inc. Compounds and methods for the synthesis of 5-(n-protected­tryptaminocarboxyamide)-2'-deoxyuridine phosphoramidite for incorporation into a nucleic acid
EP3446121A1 (en) * 2016-04-20 2019-02-27 Eisai Inc. Prognosis of serous ovarian cancer using biomarkers
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
US11935215B2 (en) 2017-08-07 2024-03-19 Imago Systems, Inc. System and method for the visualization and characterization of objects in images
AU2019339508A1 (en) 2018-09-14 2021-04-15 Prelude Corporation Method of selection for treatment of subjects at risk of invasive breast cancer
WO2020124084A1 (en) * 2018-12-15 2020-06-18 The Brigham And Women's Hospital, Inc. Augmented digital microscopy for lesion analysis
EP4182480A1 (en) 2020-07-17 2023-05-24 European Molecular Biology Laboratory Prognostic biomarkers for cancer
WO2024148280A1 (en) 2023-01-06 2024-07-11 Ideaya Biosciences, Inc. Treatment of er+ breast cancer comprising homologous recombination deficiency using parc inhibitor

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
WO1994000591A1 (en) * 1992-06-26 1994-01-06 Nippon Shinyaku Co., Ltd. Monoclonal antibody, production process, antibody-producing cell, and diagnostic method
DE69532276T2 (de) * 1994-02-14 2005-02-10 Autocyte North Carolina Llc Automatisiertes cytologisches probenklassifizierungsverfahren
US5989811A (en) 1994-09-29 1999-11-23 Urocor, Inc. Sextant core biopsy predictive mechanism for non-organ confined disease status
US5869040A (en) * 1995-06-07 1999-02-09 Biogen, Inc Gene therapy methods and compositions
JP2002514098A (ja) * 1996-08-25 2002-05-14 センサー インコーポレイテッド 虹彩取得用イメージのための装置
US5798266A (en) * 1996-08-27 1998-08-25 K-Quay Enterprises, Llc Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
EP0943095A2 (en) * 1996-11-22 1999-09-22 Shiloov Medical Technologies, Ltd. A whole blood/mitogen assay for the early detection of a subject with cancer and kit
JP5213202B2 (ja) * 1998-10-28 2013-06-19 バイシス・インコーポレーテツド 細胞アレイならびに遺伝障害マーカーの検出および使用方法
US6960449B2 (en) * 1999-02-10 2005-11-01 Cell Works Diagnostics, Inc. Class characterization of circulating cancer cells isolated from body fluids and methods of use
CA2368152A1 (en) * 1999-03-15 2000-09-21 Eos Biotechnology, Inc. Novel methods of diagnosing and treating breast cancer, compositions, and methods of screening for breast cancer modulators
US6642009B2 (en) * 1999-05-17 2003-11-04 Cytyc Health Corporation Isolated ductal fluid sample
US20030087265A1 (en) * 2000-01-21 2003-05-08 Edward Sauter Specific microarrays for breast cancer screening
JP2004512012A (ja) * 2000-04-04 2004-04-22 メディカル　リサーチ　カウンシル 細胞検出法
US6946484B2 (en) * 2000-04-26 2005-09-20 Cellegy Pharmaceuticals, Inc. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
GB0011439D0 (en) * 2000-05-12 2000-06-28 Novartis Res Found Cancer diagnosis and assays for screening
AU2001277172A1 (en) * 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-trans protein and related reagents and methods of use thereof
US6703204B1 (en) * 2000-07-28 2004-03-09 The Brigham & Women's Hospital, Inc. Prognostic classification of breast cancer through determination of nucleic acid sequence expression
DE10101792B4 (de) * 2001-01-17 2004-03-18 Vivotec Biomedical Technologies Gmbh Verfahren zum Nachweis von Pankreaskarzinom oder chronischer Pankreatitis und Verwendung von Antikörpern
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
US7514209B2 (en) * 2001-06-18 2009-04-07 Rosetta Inpharmatics Llc Diagnosis and prognosis of breast cancer patients
JP3721105B2 (ja) * 2001-08-22 2005-11-30 日本電気株式会社 組織検査法を利用する胃癌の切除手術後の予後検査方法
US7065236B2 (en) 2001-09-19 2006-06-20 Tripath Imaging, Inc. Method for quantitative video-microscopy and associated system and computer software program product
US6855554B2 (en) * 2001-09-21 2005-02-15 Board Of Regents, The University Of Texas Systems Methods and compositions for detection of breast cancer
US20040002067A1 (en) * 2001-12-21 2004-01-01 Erlander Mark G. Breast cancer progression signatures
US7133547B2 (en) * 2002-01-24 2006-11-07 Tripath Imaging, Inc. Method for quantitative video-microscopy and associated system and computer software program product
WO2003069307A2 (en) * 2002-02-14 2003-08-21 The Johns Hopkins University School Of Medicine Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer
US20040018525A1 (en) * 2002-05-21 2004-01-29 Bayer Aktiengesellschaft Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma
US20040229299A1 (en) * 2002-05-21 2004-11-18 Badal M. Youssouf Intracellular complexes as biomarkers
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP1613961A4 (en) * 2003-04-01 2007-03-07 Monogram Biosciences Inc SURFACE RECEPTOR COMPLEXES AS BIOMARKERS
CN1905876B (zh) * 2003-11-17 2010-06-09 诺瓦提斯公司 二肽基肽酶iv抑制剂的用途
US20050221398A1 (en) * 2004-01-16 2005-10-06 Ipsogen, Sas, A Corporation Of France Protein expression profiling and breast cancer prognosis
WO2005071419A2 (en) * 2004-01-16 2005-08-04 Ipsogen Protein expression profiling and breast cancer prognosis
CN1957256B (zh) * 2004-03-24 2013-01-02 三路影像公司 用于子宫颈疾病检测的方法和组合物

Also Published As

Publication number Publication date
US20060078926A1 (en) 2006-04-13
MX2007003502A (es) 2007-10-10
ATE520988T1 (de) 2011-09-15
BRPI0515581A (pt) 2008-07-29
US20090269856A1 (en) 2009-10-29
JP2008513032A (ja) 2008-05-01
AU2005289728A1 (en) 2006-04-06
EP1800130B1 (en) 2011-08-17
EP1805676A1 (en) 2007-07-11
WO2006036788A2 (en) 2006-04-06
US20060063190A1 (en) 2006-03-23
IL182062A0 (en) 2007-07-24
AU2005289756A1 (en) 2006-04-06
WO2006036788A3 (en) 2006-08-17
AU2005289756B2 (en) 2011-10-13
WO2006036726A1 (en) 2006-04-06
AU2005289728B2 (en) 2011-11-24
EP1800130A2 (en) 2007-06-27
CA2580795A1 (en) 2006-04-06
IL182063A0 (en) 2008-04-13
CA2580937A1 (en) 2006-04-06
JP2008513793A (ja) 2008-05-01
JP5184087B2 (ja) 2013-04-17
CA2580937C (en) 2016-02-02
KR20070068401A (ko) 2007-06-29
KR20070061893A (ko) 2007-06-14
US7899623B2 (en) 2011-03-01

Similar Documents

Publication Publication Date Title
BRPI0515562A (pt) métodos e composições para avaliação do prognóstico do cáncer de mama
Patschan et al. A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma
Peshkin et al. BRCA1/2 mutations and triple negative breast cancers
Donovan et al. Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy
Lotan et al. Molecular subtyping of clinically localized urothelial carcinoma reveals lower rates of pathological upstaging at radical cystectomy among luminal tumors
Glass et al. Validation of a genomic classifier for predicting post-prostatectomy recurrence in a community based health care setting
MY150234A (en) Predictive markers for ovarian cancer
Janda et al. Early detection of melanoma: a consensus report from the Australian skin and skin cancer research centre melanoma screening Summit
Ravvaz et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in a United States population
Peng et al. An expression signature at diagnosis to estimate prostate cancer patients’ overall survival
WO2005100999A3 (en) Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer
Van den Broeck et al. Validation of the Decipher test for predicting distant metastatic recurrence in men with high-risk nonmetastatic prostate cancer 10 years after surgery
MXPA06012232A (es) Uso del patron proteogenomico del plasma para diagnostico, clasificacion, prediccion de respuesta a la terapia y comportamiento clinico, estratificacion de la terapia y monitoreo de enfermedad, en malignidades hematologicas.
Saldanha et al. 5-Hydroxymethylcytosine is an independent predictor of survival in malignant melanoma
Sonpavde et al. Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy
Faba et al. High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment
Oderda et al. Cell-cycle progression-score might improve the current risk assessment in newly diagnosed prostate cancer patients
Scarisbrick et al. Developments in the understanding of blood involvement and stage in mycosis fungoides/Sezary syndrome
Sughayer et al. Applying new Magee equations for predicting the Oncotype Dx recurrence score
Ibrahim et al. Artificial intelligence-based mitosis scoring in breast cancer: Clinical application
Zheng et al. Application of nomograms to predict overall and cancer-specific survival in patients with chordoma
Roque et al. Bone scan index as metastatic bone disease quantifier and predictor of radium-223-dichloride biochemical response
Mannelli et al. Nomograms predictive for oncological outcomes in malignant parotid tumours: recurrence and mortality rates of 228 patients from a single institution
Tomasini et al. Adrenal surgery for oligometastatic tumors improves survival in selected cases
Mafra et al. Cancer survival in the northwestern of São Paulo State, Brazil: A population-based study

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 6A ANUIDADE.